EIT Health Germany announces Regional HeadStart Finalists 2018
EIT Health Germany is pleased to introduce you to the 2018 German and Swiss regional finalists of the EIT Health Germany Headstart Programme.
On 11 July 2018, EIT Health Germany hosts the regional final for German and Swiss start-ups, the “Ship for Health Innovation Pitches (SHIP)” aboard the ship “Königin Silvia” in Heidelberg. Successful applicants in the field of biotech, medtech and digital health will be invited to the SHIP to pitch their business idea in front of a jury of entrepreneurs, industry partners and investors.
As part of its Accelerator activities, EIT Health provides funding for early stage companies and SMEs to develop new products and services. Aboard the SHIP, EIT Health Germany will select the regional recipients of the 2018 Head Start Awards. The EIT Health Headstart Awards are part of EIT Health’s extensive portfolio of support programmes for emerging companies and SMEs from across Europe. The purpose of these awards is to accelerate market entry and adoption of new products and services, thus creating new economic activity.
Please find more information about the competing teams of EIT Health Germany’s Headstart Award applicants 2018 below.
The teams of EIT Health Germany’s Headstart Awards 2018 (regional finalists)
KORMORAN11 is an innovative patented product which can improve men’s health supporting active ageing by simple self testing of uroflow at home. KORMORAN11 has been co-developed by EARLIEBIRDIE, a Bavarian start-up company, together with Digmesa AG, a Swiss precision flowmeter specialist.
- IT Labs
We are developing an intelligent therapymanagement platform for all providers of the chronically ill patients. With our innovative software Alberta, we improve health care by suggesting the field care staff of homecare companies the right products for each patient’s medical conditions.
At nanoleq GmbH (ETH Zurich spin-off, www.nanoleq.com), our ambition is to provide the next generation of highly reliable cables to the market. With our newly developed cable solution, we aim at greatly improving the reliability of electrical cabling in critical healthcare systems.
ScintHealth offers a new therapy for solid tumors that are hard or impossible to operate. In those cases to reduce side-effects, the therapy of choice is chemotherapy in combination with local treatments such as embolization and ablation. ScintHealth’s product CelluRad is a beta-emitting radioactive polymer that when injected into a lesion solidifies immediately enabling a precise and highly effective local treatment with minimal side effects.
Sleepiz AG is a Zurich based award-winning Med-tech start-up founded by graduates from ETH Zurich and the University of St. Gallen (HSG), backed by leading sleep specialists in Switzerland. Sleepiz has developed a revolutionary sleep disorder screening device.
The “SHIP – Ship for Health Innovation Pitches” will be on 11 July 2018 in Heidelberg. Please register for the event by clicking the link below: